Form 4: Iovance Biotherapeutics Executive Graf Finckenstein Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer Friedrich Graf Finckenstein reports stock transactions related to vesting of restricted stock units.
Summary
- Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported transactions involving common stock and restricted stock units (RSUs) on September 3, 2024.
- The transactions involved the vesting of 3,907 RSUs and 23,438 RSUs, which converted into common stock.
- A total of 1,983 and 11,891 shares were withheld by the issuer to satisfy tax obligations at a price of $10.85 per share.
- Following these transactions, Graf Finckenstein directly owns 59,342 shares of common stock and 23,437 RSUs.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation.
Key Dates
| Date | Description |
|---|---|
| March 2, 2023 | Date of grant for some of the restricted stock units. |
| March 1, 2024 | Date of grant for some of the restricted stock units. |
| September 3, 2024 | Date of the reported transactions (vesting of RSUs and tax withholding). |
| September 5, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.